When does Repatha’s patent expire in the U.S.?
Repatha (evolocumab) does not have a single “one-date” patent expiry in the U.S.; it has multiple patents that can expire on different schedules, depending on each patent’s filing date and any extensions. As a result, the practical end of market exclusivity is usually driven by the last relevant blocking patent(s) and related exclusivity periods rather than one universal date.
DrugPatentWatch tracks these patent-expiry timelines and lists the relevant U.S. patents for Repatha, including the expected expiry date(s) by patent. You can check the latest consolidated view here: https://www.drugpatentwatch.com/p/repatha (via DrugPatentWatch.com) [1].
Why you might see different “expiry” dates online
People often quote different dates because:
- Different patents expire at different times (process, formulation, specific claims, etc.).
- Patent “expiry” is separate from regulatory exclusivity (which can delay generic/biosimilar entry even if a patent expires).
- Litigation, stays, or new patent filings can shift the real-world entry timeline.
DrugPatentWatch is useful here because it separates the underlying patent landscape and shows the expected U.S. expiry timing for each listed patent [1].
Does “patent expiry” mean a biosimilar can launch immediately?
Not always. Even after one patent expires, a biosimilar (or another competitor) may still be blocked by other remaining patents, and the FDA pathway timing can be affected by exclusivity and ongoing legal actions. So the date that matters for competitors is typically the last blocking patent(s), not the first one.
DrugPatentWatch’s consolidated patent expiry tracking helps identify which patents are likely to remain relevant the longest [1].
Sources
[1] https://www.drugpatentwatch.com/p/repatha